Back to results
CompletedPhase 3

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

1245.19.10056 Boehringer Ingelheim Investigational Site

Muscle Shoals, Alabama, United States

+67 additional locations

View on ClinicalTrials.gov
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin — TrialFind